Published by Abigail Townsend on 21st September 2026
(Sharecast News) - A treatment for a progressive eye disease that is being developed by a Sycona-backed company has delivered positive topline trial results, the life sciences investor confirmed on Monday, sending shares in the FTSE 250 firm sharply higher.
URL: http://www.digitallook.com/dl/news/story/36223152/...